The Claim
PCSK9 monoclonal antibodies and inclisiran each provide an additional 50% reduction in LDL-cholesterol levels when used in combination with maximal statin therapy, allowing high and very high-risk patients to reach guideline-recommended cholesterol targets.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Two newer cholesterol drugs, when added to the strongest statins, can cut bad cholesterol by another half — helping high-risk patients get their levels down to what doctors recommend.
See the scientific wording
Both PCSK9 monoclonal antibodies and inclisiran provide an additional 50% reduction in LDL-cholesterol levels beyond maximal statin therapy, enabling high and very high-risk patients to achieve guideline-recommended cholesterol targets.
What the research says
1 studyStudy: Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?
The study looks at the same cholesterol drugs mentioned in the claim and finds they both significantly lower bad cholesterol on top of statins, helping high-risk patients reach healthy levels.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.